Literature DB >> 26662572

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels: Effectiveness and Value.

Jeffrey A Tice1, Dhruv S Kazi2, Steven D Pearson3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26662572     DOI: 10.1001/jamainternmed.2015.7248

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN: 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  13 in total

Review 1.  Cholesterol Management in the Era of PCSK9 Inhibitors.

Authors:  Anna Svatikova; Stephen L Kopecky
Journal:  Curr Cardiol Rep       Date:  2017-09       Impact factor: 2.931

Review 2.  Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk.

Authors:  Michel Farnier
Journal:  Curr Cardiol Rep       Date:  2016-07       Impact factor: 2.931

3.  New Antilipid Drugs: Do the Known Benefits Justify the Expense?

Authors: 
Journal:  Can J Hosp Pharm       Date:  2016-08-31

4.  Bridging the Gap, Facing the Challenge-the 26(th) Great Wall International Congress of Cardiology (GW-ICC).

Authors:  Yingmei Zhang; Jun Ren
Journal:  Cardiovasc Diagn Ther       Date:  2016-02

5.  Glucose, cholesterol, and blood pressure: is lower always better for type 2 diabetes?

Authors:  Dario Giugliano; Maria Ida Maiorino; Giuseppe Bellastella; Katherine Esposito
Journal:  Endocrine       Date:  2016-05-25       Impact factor: 3.633

6.  Application of the Price-Volume Approach in Cases of Innovative Drugs Where Value-Based Pricing is Inadequate: Description of Real Experiences in Italy.

Authors:  Andrea Messori
Journal:  Clin Drug Investig       Date:  2016-08       Impact factor: 2.859

7.  Economic Evaluation of PCSK9 Inhibitors in Reducing Cardiovascular Risk from Health System and Private Payer Perspectives.

Authors:  Alejandro Arrieta; Timothy F Page; Emir Veledar; Khurram Nasir
Journal:  PLoS One       Date:  2017-01-12       Impact factor: 3.240

8.  Diallyl disulphide inhibits apolipoprotein(a) expression in HepG2 cells through the MEK1-ERK1/2-ELK-1 pathway.

Authors:  Xiaofeng Ma; Yami Liu; Yanmei Tan; Kai Qu; Xinglan He; Hai Zhang; Zuo Wang
Journal:  Lipids Health Dis       Date:  2017-11-25       Impact factor: 3.876

9.  Accelerated atherosclerosis development in C57Bl6 mice by overexpressing AAV-mediated PCSK9 and partial carotid ligation.

Authors:  Sandeep Kumar; Dong-Won Kang; Amir Rezvan; Hanjoong Jo
Journal:  Lab Invest       Date:  2017-05-15       Impact factor: 5.662

10.  Tolerability of statin-based management of patients with a history of statin-associated muscle symptoms: protocol for a systematic review.

Authors:  Fanny Villoz; Christina Lyko; Cinzia Del Giovane; Nicolas Rodondi; Manuel R Blum
Journal:  BMJ Open       Date:  2021-08-03       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.